ReviewOncoTargets and therapy2016

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor.

Kimberly A Redic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.